While well-established oncogenic pathways like c-Met/HGF, TGF-β, and FGFR remain important therapeutic targets for the development of novel therapies or combinations in HCC, several new targetable pathways have been identified for HCC in the last few years. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.